NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Immunocore Ltd
Suzhou BlueHorse Therapeutics Co., Ltd.
Takeda
Erasca, Inc.
Advenchen Laboratories, LLC
Merck Sharp & Dohme LLC